• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . The Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Epidemic and Acute Myocardial Infarct

tetano

Editor, Senior Moderator
J Infect Chemother


. 2025 Feb 26:102666.
doi: 10.1016/j.jiac.2025.102666. Online ahead of print. The Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Epidemic and Acute Myocardial Infarction: A Self-Controlled Case Series Study

Jun Suzuki[SUP] 1 [/SUP], Tomoki Mizuno[SUP] 2 [/SUP], Shota Takahashi[SUP] 3 [/SUP], Haruka Imai[SUP] 1 [/SUP], Hideya Itagaki[SUP] 4 [/SUP], Tomohiro Akaba[SUP] 5 [/SUP], Makiko Yoshida[SUP] 6 [/SUP], Shiro Endo[SUP] 7 [/SUP]



Affiliations
Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has led to various complications, including cardiovascular events. Despite the widespread impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in 2022, no studies have evaluated the relationship between the Omicron variant epidemic and acute myocardial infarction (AMI).
Methods: We utilized a Japanese claims database to identify patients diagnosed with COVID-19 between January 1, 2022, and December 31, 2022. We also identified patients who developed AMI within 90 days before and after their COVID-19 diagnosis. A self-controlled case series (SCCS) analysis evaluated the incidence rate ratio (IRR) for AMI.
Results: Of the 360,589 patients with COVID-19, 759 were diagnosed with AMI. Excluding the day of exposure, the SCCS analysis showed an IRR for AMI of 6.65 (95% confidence interval [CI]: 4.66-9.48, P<0.001) for the 1st week, 1.90 (95% CI: 1.05-3.50, P=0.03) for the 2nd week, and 0.95 (95% CI: 0.52-1.72, P=0.87) for the 3rd and 4th weeks following COVID-19. Including the day of exposure, the IRR was 77.4 (95% CI: 63.2-94.9, P<0.001) for the 1st week, 1.90 (95% CI: 1.05-3.50, P=0.03) for the 2nd week, and 0.95 (95% CI: 0.52-1.72, P=0.87) for the 3rd and 4th weeks following COVID-19.
Conclusions: This study showed that the SARS-CoV-2 Omicron variant epidemic increased AMI incidence. These findings highlight AMI as a COVID-19 characteristic, emphasize the importance of SARS-CoV-2 vaccination, and underline the need for continued vigilance, even with variant changes.

Keywords: COVID-19; acute myocardial infarction; epidemic; omicron variant.

 
Back
Top Bottom